The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments
Open accessAbstract
Impairment of cognitive processes is a devastating outcome of many diseases, injuries, and drugs affecting the central nervous system (CNS). Most often, very little can be done by available therapeutic interventions to improve cognitive functions. Here we review evidence that inhibition of glycogen synthase kinase-3 (GSK3) ameliorates cognitive deficits in a wide variety of animal models of CNS diseases, including Alzheimer's disease, Fragile X syndrome, Down syndrome, Parkinson's disease, spinocerebellar ataxia type 1, traumatic brain injury, and others. GSK3 inhibitors also improve cognition following impairments caused by therapeutic interventions, such as cranial irradiation for brain tumors. These findings demonstrate that GSK3 inhibitors are able to ameliorate cognitive impairments caused by a diverse array of diseases, injury, and treatments. The improvements in impaired cognition instilled by administration of GSK3 inhibitors appear to involve a variety of different mechanisms, such as supporting long-term potentiation and diminishing long-term depression, promotion of neurogenesis, reduction of inflammation, and increasing a number of neuroprotective mechanisms. The potential for GSK3 inhibitors to repair cognitive deficits associated with many conditions warrants further investigation of their potential for therapeutic interventions, particularly considering the current dearth of treatments available to reduce loss of cognitive functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“Besides being implicated in neurodegenerative diseases, these conditions associated with impaired neuronal function have been linked to many psychiatric and neurological diseases (Bown et al., 2000; Lin and Beal, 2006; Andreazza et al., 2010; Roussel et al., 2013).”
BackgroundVerkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 2×
“Fragile X syndrome is caused by a trinucleotide repeat expansion in the X chromosome that silences the Fragile X Mental Retardation 1 gene, suppressing expression of Fragile X Mental Retardation Protein (Pieretti et al., 1991; Verkerk et al., 1991; Mines and Jope, 2011).”
BackgroundNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“…disease is a neurodegenerative disorder characterized by progressive degeneration of nigrostriatal dopaminergic neurons that causes memory impairments, sleep abnormalities, anxiety, depression, bradykinesia, tremor, and muscular rigidity (Dawson and Dawson, 2003; Chaudhuri et al., 2006).”
BackgroundNew neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Deng, W., Aimone, J. B., & Gage, F. H. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2822 · Cited by 2,120 · cited 1×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Praag et al., 2005; Leuner et al., 2006; Deng et al., 2010; Massa et al., 2011).”
BackgroundAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
A controlled cortical impact model of traumatic brain injury in the rat
Edward Dixon, C., Clifton, G. L., Lighthall, J. W., Yaghmai, A. A., & Hayes, R. L. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90104-8 · Cited by 1,141 · cited 2×
“TBI results from direct damage to the brain that causes many pathological effects that can continue to evolve over time, including changes in neuronal architecture and death, which contribute to learning and memory deficits (Dixon et al., 1991; Thompson et al., 2005; Blennow et al., 2012).”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913
Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803
The Neuropathology and Neurobiology of Traumatic Brain Injury
Blennow, K., Hardy, J., & Zetterberg, H. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.021 · Cited by 669
Sustained attention deficit in bipolar disorder
Clark, L., Iversen, S. D., & Goodwin, G. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.4.313 · Cited by 539
Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau
Mandelkow, E.-M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., Vandenheede, J. R., & Mandelkow, E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81496-9 · Cited by 515
Andreazza, A. C., Shao, L., Wang, J.-F., & Young, L. T. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.22 · Cited by 448
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442
Endoplasmic reticulum dysfunction in neurological disease
Roussel, B. D., Kruppa, A. J., Miranda, E., Crowther, D. C., Lomas, D. A., & Marciniak, S. J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70238-7 · Cited by 441 · cited 1×
“Besides being implicated in neurodegenerative diseases, these conditions associated with impaired neuronal function have been linked to many psychiatric and neurological diseases (Bown et al., 2000; Lin and Beal, 2006; Andreazza et al., 2010; Roussel et al., 2013).”
BackgroundGSK-3 is a master regulator of neural progenitor homeostasis
Kim, W.-Y., Wang, X., Wu, Y., Doble, B. W., Patel, S., Woodgett, J. R., & Snider, W. D. (2009) · Nature Neuroscience · doi:10.1038/nn.2408 · Cited by 399
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · cited 1×
“This study established the safety and tolerability of this GSK3 inhibitor, and although there were trends towards improvement, further trials will be required to determine if cognitive impairments in AD are significantly improved (del Ser et al., 2013).”
BackgroundProtein kinase C overactivity impairs prefrontal cortical regulation of working memory
Birnbaum, S. G., Yuan, P. X., Wang, M., Vijayraghavan, S., Bloom, A. K., Davis, D. J., Gobeske, K. T., Sweatt, J. D., Manji, H. K., & Arnsten, A. F. T. (2004) · Science · doi:10.1126/science.1100021 · Cited by 318 · cited 2×
“5 mEq/kg; orally; 3 times/day) of 8 rhesus monkeys between the ages of 13 and 30 years restored working memory on the delayed response task after impairment induced by cirazoline treatment, an adrenergic receptor agonist (Birnbaum et al., 2004).”
BackgroundInfluentialAβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β
Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305
Ma, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262
Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., & Imahori, K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12257-5 · Cited by 260 · cited 2×
“GSK3 is intimately linked to AD neuropathology, as Aβ increases GSK3β activity (Takashima et al., 1996), GSK3 promotes the production of Aβ (Phiel et al., 2003), and GSK3 promotes apoptotic signaling induced by Aβ (reviewed in Mines et al., 2011).”
BackgroundThe evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Raison, C. L., & Miller, A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.2 · Cited by 253 · cited 1×
“Inflammation is well-known to accompany and exacerbate neurodegenerative diseases, such as AD, and neuroinflammation is also now recognized as an important component of the disease process in psychiatric diseases, such as depression (Raison and Miller, 2013) and schizophrenia (Mansur et al., 2012).”
BackgroundYuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240 · cited 1×
“Thus, GSK3 inhibitors diminish many inflammatory responses by both astrocytes and microglia in the CNS, as well as by peripheral immune cells, reducing inflammation in the CNS (Beurel and Jope, 2009; Cheng et al., 2009; Yuskaitis and Jope, 2009).”
BackgroundZhu, L.-Q., Wang, S.-H., Liu, D., Yin, Y.-Y., Tian, Q., Wang, X.-C., Wang, Q., Chen, J.-G., & Wang, J.-Z. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3321-07.2007 · Cited by 234
Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215
Inflammation Induced by Infection Potentiates Tau Pathological Features in Transgenic Mice
Sy, M., Kitazawa, M., Medeiros, R., Whitman, L., Cheng, D., Lane, T. E., & LaFerla, F. M. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.012 · Cited by 210 · cited 4×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript induced impairment in the Morris water maze (Sy et al., 2011).”
BackgroundMethodInfluentialGlycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells
Beurel, E., Yeh, W.-I., Michalek, S. M., Harrington, L. E., & Jope, R. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003511 · Cited by 86
Self-citation
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Self-citationGSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
The S100B story: from biomarker to active factor in neural injury
Michetti, F., D'Ambrosi, N., Toesca, A., Puglisi, M. A., Serrano, A., Marchese, E., Corvino, V., & Geloso, M. C. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14574 · Cited by 410
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
A synaptic perspective of fragile X syndrome and autism spectrum Disorders.
Bagni, C., & Zukin, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.041 · Cited by 326
“It is therefore not surprising that dysregulation of GSK3β contributes to a number of diseases such as mood disorders, schizophrenia and Alzheimer disease (King et al., 2014).”
Background
Metadata
- Authors
- King, M. K., Pardo, M., Cheng, Y., Downey, K., Jope, R. S., & Beurel, E.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 141
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1998006367
- Cited by
- 171
- References
- 27
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.